Galera Therapeutics GRTX Stock
Galera Therapeutics Price Chart
Galera Therapeutics GRTX Financial and Trading Overview
| Galera Therapeutics stock price | 0.16 USD |
| Previous Close | 3.27 USD |
| Open | 3.29 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 1300 |
| Day's Range | 3.25 - 3.41 USD |
| 52 Week Range | 1.12 - 3.59 USD |
| Volume | 446.45K USD |
| Avg. Volume | 598.1K USD |
| Market Cap | 145.45M USD |
| Beta (5Y Monthly) | 1.819053 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.33 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.75 USD |
GRTX Valuation Measures
| Enterprise Value | 236.41M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.7035177 |
| PEG Ratio (5 yr expected) | -0.05 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -4.56 |
Trading Information
Galera Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.819053 |
| 52-Week Change | 145.65% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.59 USD |
| 52 Week Low | 1.12 USD |
| 50-Day Moving Average | 3.01 USD |
| 200-Day Moving Average | 2.12 USD |
GRTX Share Statistics
| Avg. Volume (3 month) | 598.1K USD |
| Avg. Daily Volume (10-Days) | 482.36K USD |
| Shares Outstanding | 42.91M |
| Float | 34.33M |
| Short Ratio | 1.1 |
| % Held by Insiders | 3.45% |
| % Held by Institutions | 31.63% |
| Shares Short | 812.61K |
| Short % of Float | 1.91% |
| Short % of Shares Outstanding | 1.89% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -49.64% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -51850000 USD |
| Net Income Avi to Common (ttm) | -64489000 USD |
| Diluted EPS (ttm) | -2.12 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 47.75M USD |
| Total Cash Per Share (mrq) | 1.11 USD |
| Total Debt (mrq) | 143.86M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 4.089 |
| Book Value Per Share (mrq) | -2.275 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -43707000 USD |
| Levered Free Cash Flow (ttm) | -33631500 USD |
Profile of Galera Therapeutics
| Country | United States |
| State | PA |
| City | Malvern |
| Address | P.O. Box 134 |
| ZIP | 19355 |
| Phone | 610 725 1500 |
| Website | https://www.galeratx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 31 |
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Q&A For Galera Therapeutics Stock
What is a current GRTX stock price?
Galera Therapeutics GRTX stock price today per share is 0.16 USD.
How to purchase Galera Therapeutics stock?
You can buy GRTX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Galera Therapeutics?
The stock symbol or ticker of Galera Therapeutics is GRTX.
Which industry does the Galera Therapeutics company belong to?
The Galera Therapeutics industry is Biotechnology.
How many shares does Galera Therapeutics have in circulation?
The max supply of Galera Therapeutics shares is 54.39M.
What is Galera Therapeutics Price to Earnings Ratio (PE Ratio)?
Galera Therapeutics PE Ratio is now.
What was Galera Therapeutics earnings per share over the trailing 12 months (TTM)?
Galera Therapeutics EPS is -1.33 USD over the trailing 12 months.
Which sector does the Galera Therapeutics company belong to?
The Galera Therapeutics sector is Healthcare.
Galera Therapeutics GRTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}